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Abstract
In  Russian  Federation,  27,300,000–41,200,000  acute  upper  and  lower  respiratory
infections are reported annually. Patients with chronic obstructive pulmonary disease
(COPD) are at  higher risk of  severe course,  complications,  and lethal  outcomes of
influenza. About 30% of COPD exacerbations are due to viral infections, and influenza
A and B viruses are among the most common causes. The aim of our study was to assess
exacerbation rate, number of courses of antibiotic chemotherapy, pulmonary function,
and immunological effects of mono-vaccination with a new immunoadjuvant influenza
vaccine vs. combined vaccination against pneumococcal infection, Hemophilus type b
infection, and influenza in COPD patients. Both complex vaccination against Strepto-
coccus  pneumoniae,  Haemophilus  influenzae  type  b,  and  influenza  and  mono-
vaccination with a new immunoadjuvant influenza vaccine led to statistically significant
reduction  in  the  number  of  COPD  exacerbations  and  of  antibiotic  chemotherapy
courses. Based on the obtained results, widespread implementation of mono-vaccina-
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tion  against  influenza  with  a  new  immunoadjuvant  influenza  vaccine,  as  well  as
complex  vaccination  against  bacterial  respiratory  infections  and  influenza  can  be
recommended for COPD patients, as vaccination is beneficial for their functional status,
that is, improves forced expiratory volume in 1 s (FEV1) and 6-minute walk test results.
In our study, we evaluated immunogenicity of the new influenza immunoadjuvant
vaccine administered as mono-vaccine to COPD patients in accordance with Committee
for Proprietary Medicinal Products (CPMP) requirements.
Keywords: chronic obstructive pulmonary disease (COPD), vaccination, influenza,
clinical effects, immunological effects
1. Introduction
In Russia, 27,300,000–41,200,000 acute upper and lower respiratory infections are reported
annually. Patients with chronic obstructive pulmonary disease (COPD) are at higher risk of
severe course, complications, and lethal outcomes of influenza. Therefore, influenza prevention
in such patients is one of the most urgent tasks.
About 30% of COPD exacerbations are due to viral infections, and influenza A and B viruses
are among the most common causes.
The best approach to prophylaxis is provided by vaccination because it combines the advan-
tages of specificity, efficacy, safety, and cost-effectiveness. The GOLD guidelines (Global
Initiative for Chronic Obstructive Lung Disease) recommend that influenza vaccination
preferentially with split or subunit vaccines must be integrated into treatment strategies for
all COPD patients regardless of the disease stage. However, further studies are needed to
evaluate the efficacy and immunogenicity of modern adjuvant influenza vaccines [1].
It is not rarely that the risk of COPD exacerbation is associated not directly with the influenza
virus as such, but rather with the development of bacterial superinfection, mainly caused by
Streptococcus pneumoniae or Haemophilus influenzae type b [2–4].
In the Russian Federation, both inactivated and live vaccines against influenza have been
licensed [5]. Antigenic composition of these vaccines is modified annually to adopt current
epidemic situation and WHO guidelines. Recently, an innovative new class of immunoadju-
vant influenza vaccines has evolved. The use of these vaccines in COPD patients will be
outlined below.
According to CPMP criteria (Committee for Proprietary Medicinal Products), a vaccine is
considered immunogenic, if at least one of the assessments meets the indicated requirements:
1. Seroconversion rate (at least fourfold increase in anti-hemagglutinin antibody titre): over
40% for individuals aging 18–60 years and over 30% among individuals above 60 years.
2. Seroprotection rate (number of individuals with protective titre of at least 1:40): over 70%
for individuals aging 18–60 years and over 60% in individuals above 60 years.
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3. Mean titre increase after vaccination: ≥2.5 in individuals aging 18–60 years and ≥2 in
individuals above 60 years.
Vaccination against influenza for COPD patients is included into the National Immunization
Calendar of the Russian Federation.
S. pneumoniae, H. influenzae, M. catarrhalis, and influenza virus are the most common causes
of COPD infective exacerbations [6]. The standard of care for COPD patients includes vacci-
nation against influenza and pneumococcal infection. Several serotypes of H. influenzae are
known, and COPD exacerbation may be caused by each of them, including H. influenzae type
b. Vaccine against H. influenzae type b is now available; therefore, it is of interest to evaluate
a combined vaccination against S. pneumoniae, H. influenzae, and influenza in COPD patients
and the effects of these vaccines on exacerbation rate and pulmonary function tests.
In adult COPD patients, the pioneer studies evaluating the therapeutic effect of PPV23 were
performed in 2004. Elimination of S. pneumoniae from the sputum was observed in 52.9%
cases, that is, at a lower rate compared to children. Other findings include increased levels of
IgG against S. pneumoniae serotypes 3, 6B, 9N, 23F; decreased total IgE, and increased Wright’s
phagocytic index [7].
Immunization of COPD patients with PPV23 contributed to a 2.2-fold decrease in exacerbation
rate by 18 months; at 12 months post vaccination, the duration of acute episodes decreased 1.8-
fold compared to the control group [8].
Though disputable, the preliminary results regarding therapeutic effects of vaccination against
respiratory infections were thus obtained. The common controversy is whether it is possible
to improve the respiratory function tests in COPD patients through vaccination.
Study aim—to assess exacerbation rate, number of courses of antibiotic chemotherapy,
pulmonary function, and immunological effects of mono-vaccination with a new immunoad-
juvant influenza vaccine vs. combined vaccination against pneumococcal infection, Haemo-
philus type b infection, and influenza in COPD patients.
2. Material and methods
The study enrolled 170 patients with grade 1, 2, 3, 4 COPD (age 30–80 years) who had signed
informed consent according to the study protocol approved by the ethics committee of the
Samara State Medical University (Russian Federation) and Research Institute of Pulmonology
(Moscow, Russian Federation). The diagnosis was determined according to GOLD guidelines
(2012) [9].
Patients were divided into four groups. Group I enrolled 50 patients with COPD who contin-
ued to receive basic therapy for the main disease and were vaccinated with commercially
available vaccines against pneumococcal infection (Pneumo 23, France), H. influenzae type b
infection (Hiberix, Belgium), and influenza (new immunoadjuvant vaccine Grippol® plus,
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Russian Federation). Vaccines were administered once intramuscularly into various parts of
the body. Two patients from Group I did not complete the study per protocol (one patient died
after a traffic accident, and one patient died from sudden massive pulmonary embolism).
Therefore, the data from these patients were not included into final analysis, and it was based
on 48 patients of Group I.
Group II (control for patients who received complex vaccination against pneumococcal
infection, Haemophilus type b infection, and influenza) consisted of 80 patients with COPD
of similar grade, who were not vaccinated and received only basic therapy.
Group III consisted of 20 COPD patients vaccinated against influenza with a new immunoad-
juvant vaccine. Group IV (control for patients who received mono-vaccination against
influenza with a new immunoadjuvant vaccine) enrolled 20 unvaccinated COPD patients.
Groups II and IV were composed of patients who categorically rejected any vaccination,
despite the information provided. Nevertheless, these patients gave their consent to participate
in the study. All study patients were followed up for 1 year and subjected to function and
immunological tests at baseline and at 12 months.
The use of two control groups was associated with enrollment of patients in two various study
centers. Each study center enrolled subjects either to Group I (group of complex vaccination
and control group) or to Group III (group of mono-vaccination against influenza and control
group). Another reason for the use of two control groups was the probability that baseline
characteristics of the patients in Group 1 and Group 3 will not be well balanced, and their
comparison with the total control group will be incorrect. Our study is not a direct comparison
between the groups of complex vaccination and mono-vaccination. We just compare each of
these groups with its own control.
All study patients underwent a history taking (identification of risk factors for COPD,
complaints for cough, sputum discharge, dyspnea of any grade worsened by physical
exercise). To verify the diagnosis of COPD, all patients were subjected to pulmonary function
tests and broncholytic test with 400 μg of salbutamol according to the standard techniques [8].
The study enrolled patients with Tiffeneau index forced expiratory volume in 1 s/forced vital
capacity (FEV1/FVC) below 70%.
Inclusion criteria:
• Men and women above 30 years of age.
• Patients with mild/moderate/severe/extremely severe COPD.
• Patient’s informed consent.
Exclusion criteria:
• Age below 30 years.
• Vaccination against pneumococcal infection within the previous 3 years.
• Previous vaccination against H. influenzae type b infection.
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• Acute infectious diseases and tuberculosis.
• Active phase of chronic virus hepatitis.
• Mental disorders.
• Renal or hepatic failure.
• Malignancies.
• Exacerbation of chronic diseases.
• Hypersensitivity to vaccine components.
• Severe complications of previous vaccination.
• Pregnancy.
• Autoimmune disorders.
Patients were followed up by general practice physicians, pulmonologists, or allergologists-
immunologists in the outpatient context or in hospitals, if hospitalization was required. In
cases of COPD exacerbation, if necessary, patients were hospitalized to departments of
pulmonology.
Patients meeting inclusion/exclusion criteria were divided into four groups. Groups II and IV
enrolled patients who categorically rejected any vaccination. Other patients were first recruited
to Group I to undergo complex vaccination and then to Group III to be vaccinated against
influenza using a new immunoadjuvant vaccine. Sample size was determined by the number
of vaccines.
All patients received basic bronchodilatory and anti-inflammatory therapies in accordance
with the disease severity and GOLD guidelines (2012). At baseline, groups were well balanced
for age, gender, disease severity, and scope of basic therapy, which remained unchanged
throughout the study period. Vaccination was performed at remission in the outpatient
context, follow-up period lasted for 12 months after vaccination.
PPV23 vaccine is a polyvalent pneumococcal vaccine manufactured by Sanofi aventis (France).
It contains purified capsule S. pneumoniae polysaccharides of 23 serotypes. One dose of
vaccine is 0.5 ml.
Hiberix is a conjugated vaccine to prevent infections caused by H. influenzae type b
(GlaxoSmithKline Biologicals s.a., Belgium). One dose contains 10 μg of purified capsule
polysaccharide isolated from str. H. influenzae type b conjugated with 30 μg of tetanus
toxoid.
Grippol plus vaccine (NPO Petrovax Pharm, Russia) is a trivalent polymeric subunit immu-
noadjuvant vaccine (Petrovax, Russia) containing protective antigens isolated from purified
influenza type A and B viruses grown in chicken embryos. One immunization dose (0.5 ml)
contains at least 5 μg of hemagglutinin of epidemiologically relevant influenza subtype A
(H1N1 and H3N2) and type B viruses, and polyoxidonium immunoadjuvant 500 μg in sodium
phosphate buffer. Vaccine is free of preservatives.
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Clinical efficacy of vaccination was assessed by the number of COPD exacerbations during the
year before vaccination and after vaccination. COPD exacerbation was defined as increased
dyspnea, cough, and sputum volume requiring medical advice and modification of current
therapy documented by primary medical records.
Ventilation function was investigated using a Spiro S-100 spirometer (Russian Federation). The
following parameters were measured: forced vital capacity (FVC), forced expiratory volume
in 1 s (FEV1), and a calculated ratio of these two parameters (FEV1%/FVC), that is, modified
Tiffeneau test. Exercise tolerance was assessed using the 6-minute walk test (6MWT) according
to the standard protocol.
The levels of IgG antibodies against influenza virus strains were measured using standard HAI
assay (hemagglutination inhibition assay) in accordance with the manufacturer’s instructions
to the kit.
The results were studied statistically using StatPlus 2009 Professional 5.8.4. Measures of central
tendency and dispersion were chosen depending on the data distribution type. Continuous
variables corresponding to normal distribution are presented as means (SD); variables
differing from normal distribution as medians (interquartile distance). Categorical variables
are presented as proportions (%) and absolute values.
The choice of statistical test depends on the data distribution type and evaluation of dispersion
equality. The hypothesis of data distribution normality was tested (Shapiro-Wilks test). In cases
of normal distribution of data in each sample, dispersion is to be compared between two
distributions (Levene’s test). If both criteria are met, Student’s t test is selected, if no, its non-
parametric alternative is used (Mann-Whitney test). The same is applicable to paired tests for
comparisons of changing variables (pairwise Student’s t test or Wilcoxon test for paired
comparisons). Comparative analysis of categorical variables was performed using exact two-
sided Fisher’s test. Differences were statistically significant at p < 0.05 [10].
Prospective study design allows calculating the following statistics:
• Number of patients with exacerbations per year before and after vaccination.
• Absolute risk (AR) of exacerbation per year before and after vaccination.
• Relative risk (RR) of exacerbation per year before and after vaccination.
• Reduction of absolute risk (RAR) of exacerbation after vaccination.
• Reduction of relative risk (RRR) of exacerbation after vaccination.
• Chance of exacerbation.
• Odds ratio (OR) for exacerbation after vaccination compared to no vaccination.
• Number of patients needed to treat to prevent one additional bad outcome (NNTp).
About 95% CI of the difference of absolute risks (AR): the results are statistically significant, if
95% CI will not contain 0.
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About 95% CI of the relative risk (RR): the results are statistically significant, if 95% CI will not
contain 1.
About 95% CI for the odds ratio (OR): the results are statistically significant, if 95% CI will not
contain 1.
 
3. Results and discussion
3.1. Clinical effects of vaccination in COPD patients
The clinical effects of vaccination (exacerbation rate) in COPD patients are characterized by
groups in Table 1.
Table 1. Number of exacerbations (calculated statistics) in COPD patients per year before and after vaccination.
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Both complex and mono-vaccination resulted in a statistically significant reduction of the
number of COPD exacerbations. The risk of COPD exacerbation was reduced by 54% after
complex vaccination vs. 30% after mono-vaccination (p > 0.05 for all comparisons).
Table 2. Number of courses of antibiotic chemotherapy (calculated statistics) in COPD patients per year before and
after vaccination in the groups considered.
As compared to unvaccinated patients, complex vaccination reduced the risk of COPD
exacerbation by 59 vs. 38% reduction after mono-vaccination vs. increase by 6% in unvacci-
nated patients.
In the group of complex vaccination against pneumococcal, Haemophilus type b infection, and
influenza, the chance of COPD exacerbation was 5% of that in unvaccinated patients (p < 0.05).
In the group of mono-vaccination, the chance of COPD exacerbation was 25% of that without
vaccination (p > 0.05).
Table 2 presents characteristics of the clinical effect of vaccination (i.e., number of courses of
antibiotic chemotherapy) in different groups of COPD patients.
Both complex and mono-vaccination led to statistically significant reduction in the number of
antibacterial chemotherapy courses.
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The risk of antibiotic chemotherapy was reduced by 54% in the group of complex vaccination
against pneumococcal, Hemophilus type b infection, and influenza vs. 30% in the group of
mono-vaccination (p > 0.05 for all comparisons).
As compared to no vaccination, complex vaccination reduced the risk of antibiotic chemo-
therapy in patients with COPD by 64%, whereas mono-vaccination reduced it by 35%.
In the group of complex vaccination against pneumococcal, Hemophilus type b infection, and
influenza, the chance of antibiotic chemotherapy was 8% of that in unvaccinated patients (p <
0.05). In the group of mono-vaccination, the chance of antibiotic chemotherapy was 21% of that
in unvaccinated (p < 0.05).
3.2. The effect of vaccination on the pulmonary function tests in COPD patients
In COPD patients from Groups I and II, FVC changes did not undergo any statistically
significant changes over 12 months (Table 3). In Group I (patients vaccinated against pneu-
mococcal, Hemophilus type b infection, and influenza), forced expiratory volume in 1 s (FEV1)
increased to 57.4% (2.0%) at 12 months vs. 53.9% (2.7%) at baseline (p < 0.05). In unvaccinated
patients (Group II), these parameters remained unchanged: 54.1% (1.9%) at baseline vs. 50.4%
(2.8%) at 12 months (p > 0.05), indicating that the rate of FEV1 decrease was lower in vaccinated
COPD patients (Group I). Detailed characteristics of FEV1 changes in Groups I and II depend-
ing on the disease severity are given in Table 4, and Table 5 outlines the same for Tiffeneau
index.
COPD grade At baseline At 12 months
Abs., ml % Abs., ml %
1 (n = 3/n = 24) 3611 (466) 100.7 (3) 3724 (489) 104 (0.4)
3608 (206) 97.8 (3.2) 3572 (176) 95.6 (2.9)
2 (n = 23/n = 25) 2943 (180) 78.9 (3.3) 2867 (169) 79.3 (3.3)
2936 (173) 77.9 (4.1) 2918 (167) 76.9 (3.5)
3 (n = 18/n = 25) 2301 (129) 55.2 (2.8) 2173 (208) 53.3 (3.5)
2311 (128) 55.2 (2.7) 2086 (96.2) 51.2 (2.6)
4 (n = 4/n = 6) 1854 (116) 46.6 (5.6) 2158 (119)& 55.8 (3.8)&
1845 (129) 45.2 (5.1) 1778 (106) 43.3 (2.2)
Total (n = 48/n = 80) 2653 (119) 68.7 (2.9) 2602 (131) 68.3 (2.9)
2648 (122) 67.9 (2.5) 2562 (131) 64.8 (2.2)
Data are presented as means (standard deviation).
Group I patients in the numerator, Group II patients in the denominator.
& p < 0.05—differences between Groups I and II (Student’s test).
Table 3. FVC changes in COPD patients from Groups I and II over 12 months.
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COPD grade At baseline At 12 months
Abs., ml % Abs., ml %
1 (n = 3/n = 24) 2412 (236)     86.7 (1.6)     2597 (337)     90.5 (1.1)&&
2399 (205) 85.8 (2.0) 2384 (136) 85.4 (1.2)
2 (n = 23/n = 25) 1954 (112) 66.1 (2.1) 1985 (109) 69.9 (2.6)&
1959 (110) 66.4 (2.7) 1916 (102) 62.9 (1.4)
3 (n = 18/n = 25) 1274 (65.1) 39.1 (1.4) 1314 (101) 42.0 (2.2)
1280 (69.3) 40.0 (1.3) 1204 (76.3) 37.2 (1.6)
4 (n = 4/n = 6) 876 (106.5) 26.9 (1.4) 951 (106.5) 28.6 (2.7)
883 (115.5) 27.9 (1.2) 826 (97.2) 25.9 (1.0)
Total (n = 48/n = 80)       1638 (86.6) 53.9 (2.7) 1685 (95.4) 57.4 (2.0)&
1642 (92.5) 54.1 (1.9) 1574 (94.4) 50.4 (2.8)
Data are presented as means (standard deviation).
Group I patients in the numerator, Group II patients in the denominator.
& p < 0.05; && p < 0.01—differences between Groups I and II (Student’s test).
Table 4. FEV1 changes in COPD patients from Groups I and II over 12 months.
COPD grade At baseline At 12 months
% %
1 (n = 3/n = 24) 67.27 (1.95) 69.8 (0.1)
66.34 (2.18) 68.4 (0.89)
2 (n = 23/n = 25) 67.14 (2.04) 69.9 (2.29)&
66.85 (1.95) 64.24 (1.58)
3 (n = 18/n = 25) 56.68 (2.59) 62.39 (2.61)
55.43 (2.12) 58.4 (2.53)
4 (n = 4/n = 6) 47.85 (6.69) 44.2 (4.95)
47.38 (5.12) 45.84 (2.53)
Total (n = 48/n = 80) 61.62 (1.73) 64.93 (1.94)&
60.98 (1.85) 59.13 (2.15)
Data are presented as means (standard deviation).
Group I patients in the numerator, Group II patients in the denominator.
& p < 0.05—differences between Groups I and II (Student’s test).
Table 5. Tiffeneau index changes in COPD patients from Groups I and II over 12 months.
One year post vaccination, vaccinated COPD patients (Group I) showed 6MWT results that
were 75.2% (2.8%) of the desired values vs. 60.4% (2.3%) in Group II patients (p < 0.001). Detail
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characteristics of the dynamics of the 6-minute walk test depending on the disease severity are
given in Table 6.
COPD grade At baseline At 12 months
Abs., m % Abs., m %
1 (n = 3/n = 24) 440 (49.0) 86.1 (8.6) 450 (54.5) 92.8 (4.3)
434 (52.8) 84.7 (9.1) 429 (41.2) 83.5 (4.2)
2 (n = 23/n = 25) 355 (13.1) 71.8 (2.4) 401 (15.8)*,&&& 81.2 (3.1)*, &&&
351 (10.2) 70.9 (2.6) 324 (8.7)# 64.1 (1.2)#
3 (n = 18/n = 25) 314 (21.1) 64.0 (3.8) 338 (26.4) 69.7 (4.3)&
319 (20.3) 64.1 (3.6) 296 (17.1) 59.4 (1.7)
4 (n = 4/n = 6) 230 (45.2) 47.4 (13) 266 (37.3) 54 (12.3)
235 (40.3) 48.6 (10.3) 213 (10.5) 44.2 (2.3)
Total (n = 48/n = 80) 335 (12.6) 67.8 (2.4) 369 (14.5)&&& 75.2 (2.8)*, &&&
332 (18.4) 66.3 (2.6) 305 (10.5) 60.4 (2.3)
Data are presented as means (standard deviation).
Group I patients in the numerator, Group II patients in the denominator.
* p ˂ 0.05 vs. baseline values in Group I (Student’s test).
# p < 0.05 vs. baseline values in Group II (Student’s test).
& p ˂ 0.05; &&& p < 0.001—differences between Groups I and II (Student’s test).
Table 6. Dynamics of 6MWT in COPD patients from Groups I and II over 12 months.
Detailed characteristics of spirometry data in COPD patients from Groups III and IV are pre-
sented in Table 7.
Parameter Vaccinated against influenza (Group III, n = 20) Unvaccinated (Group IV, n = 20)
At baseline At 12 months At baseline At 12 months
FVC  Abs. 1.62 (0.18) 1.71 (0.13) 2.05 (0.12) 1.88 (0.16)
 % 37.69 (3.61) 42 (2.74) 47.06 (2.9) 41.94 (3.05)
FEV1  Abs. 1.13 (0.13) 1.17 (0.08) 1.48 (0.1) 1.38 (0.11)
 % 33.65 (3.43) 35.76 (2.16) 42.25 (2.76) 40.83 (3.46)
FEV1/FVC  % 52.7 (3.42) 46.46 (3.2)& 55.8 (2.18) 57.9 (2.66)
Data are presented as means (standard deviation).
& p < 0.05—differences between Groups III and IV at 12 months (Student’s test).
Table 7. Spirometry values in COPD patients vaccinated against influenza (Group III) and in unvaccinated control
patients (Group IV).
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The analysis of the 6-minute walk test results showed a trend to distance increase by 13 m
(+3.7%) 1 year after mono-vaccination (p > 0.05, Student’s test).
Thus, the study demonstrated statistically significant increase in FEV1 [57.4% (2.0%)] at
12 months after complex vaccination when compared to unvaccinated COPD patients [50.4%
(2.8%)]. This FEV1 increase was 3.5%, that is, not statistically significant vs. baseline value,
although the positive trend was observed.
The group of mono-vaccination against influenza also demonstrated the positive trend of FEV1
increase, but the increase was only 2.11%, which is less than 3.5% in the group of complex
vaccination.
In the group of complex vaccination, patients demonstrated significantly improved 6MWT
results at 12 months vs. baseline distance. In Group I, the increase was 7.4% (+34 m), that is,
statistically significant (p < 0.05). In patients vaccinated against influenza, 6MWT increase
approached trend levels of significance.
3.3. Immunological effect of vaccination in patients with COPD
Previously, we have reported the dynamics of specific antibodies against influenza virus in
COPD patients after complex vaccination against S. pneumoniae, H. influenzae type b, and
influenza [11].
Combined vaccination against pneumococcal, H. influenzae type b and influenza is accom-
panied by production of antibodies to these infections, which persist during 1 year (observation
period), regardless of disease severity. In patients with stage 4 COPD, the level of antibodies
to influenza virus (strains A/H1N1, A/H3N2 and B) in post-vaccination period was lower than
in patients with stages 1, 2, and 3. Probably, these patients should be vaccinated against
influenza twice. Despite the fact that patients with COPD had lower levels of post-vaccination
antibodies than control, they demonstrated apparent clinical effect throughout 12 months,
which was recorded as reduction of both exacerbation number and the need in antibacterial
medications. Combined vaccination against bacterial and viral infections contributes to the
achievement of antibody levels leading to the development of significant clinical effect in
patients with COPD.
Table 8 demonstrates lists immunogenicity parameter of the new immunoadjuvant vaccine
against influenza after mono vaccination of COPD patients.
No statistically significant differences in immunogenicity were found between COPD patients
and healthy participants vaccinated only against influenza, the latter, however, demonstrated
a trend toward higher immune response to vaccination.
In the comparative analysis of COPD patients, in whom antibodies to all three influenza virus
strains were detected at arbitrarily protective titres (≥1:40) at 6 months after vaccination, and
patients, in whom, despite vaccination, antibody titres were <1:40, COPD patients at risk of
low response to vaccination were identified. These patients had a long history of COPD with
frequent respiratory infections and COPD exacerbations requiring hospitalization and
systemic glucocorticosteroids or antibiotic chemotherapy.
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Vaccine
strains
Seroconversion, %
(N ≥ 40%)
Seroprotection, %
(N ≥ 70%)
Mean geometric antibody titre (N ≥ 40)
6 months 12 months 6 months 12 months At baseline 6 months 12 months
A/H1N1/
Brisbane/
59/07 
60 ± 16 40 ± 16 58 ± 14 67 ± 14 20 (log2
4.32 ± 0.36)
30.64 (log2
4.94 ± 0.38)
33.64^p(log2
5.07 ± 0.28)
A/H3N2/
Uruguay/
716/2007
70 ± 15 50 ± 16 75 ± 13 83.3 ± 11 24.75 (log2
4.63 ± 0.63)
71.91 (log2
6.17 ± 0.62)
59.93 (log2
5.91 ± 0.38)
B/Florida/
4/2006
30 [15; 45] 10 [1; 20] 100 ± 0 100 ± 0 46.94 (log2
5.55 ± 0.30)
84.38 (log2
6.4 ± 0.33)
59.9 (log2
5.91 ± 0.38)
Marked values meet CPMP requirements.
Table 8. Immunogenicity parameters of the new immunoadjuvant vaccine against influenza after mono-vaccination of
COPD patients (n = 15).
4. Conclusions
During post-vaccination period, treating physicians and patients as well focus their attention
on the main disease course. The clinical course of the disease may be characterized by number
of COPD exacerbations and the need for antibiotic chemotherapy. Both complex vaccination
against S. pneumoniae, H. influenzae type b, and influenza and mono-vaccination with a new
immunoadjuvant influenza vaccine led to statistically significant reduction in the number of
COPD exacerbations and of antibiotic chemotherapy courses.
Our study had some limitations, that is, its pilot character, absence of randomization and
blinding, and small sample size. As follows from the study results, complex vaccination of
COPD patients against bacterial and viral respiratory infections have more expressed
beneficial effects on their functional status when compared to mono-vaccination against
influenza. Further well-designed multicenter clinical studies devoid of these limitations are
needed to refine the hypothesis. Nevertheless, based on the obtained results, widespread
implementation of mono-vaccination against influenza with a new immunoadjuvant influenza
vaccine, as well as complex vaccination against bacterial respiratory infections and influenza
can be recommended for COPD patients, as vaccination is beneficial for their functional status,
that is, improves FEV1 and 6-minute walk test results.
Mono-vaccination of COPD patients using immunoadjuvant vaccines of a new class as well as
combined vaccination against S. pneumoniae, H. influenzae, and influenza is associated with
protective antibody titres. In our study, we evaluated immunogenicity of the new influenza
immunoadjuvant vaccine administered as mono-vaccine to COPD patients in accordance with
CPMP requirements. Immune response to vaccine strains of influenza virus was more intense
and durable in initially seropositive patients compared to seronegative.
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Combined vaccination against pneumococcal, H. influenzae type b and influenza is accom-
panied by production of antibodies to these infections. In patients with stage 4, COPD the level
of antibodies to influenza virus (strains A/H1N1, A/H3N2 and B) in post-vaccination period
was lower than in patients with stages 1, 2, and 3. Probably, these patients should be vaccinated
against influenza twice. Combined vaccination against bacterial and viral infections contrib-
utes to the achievement of antibody levels leading to the development of significant clinical
effect in patients with COPD.
Influenza prophylaxis in COPD patients implies annual influenza vaccination of all individ-
uals having no contraindications regardless of the disease severity. Influenza vaccine prophy-
laxis must be included into patient’s care plan and into the list of recommendations given by
a pulmonologist at an outpatient visit or at discharge from hospital. If possible, simultaneous
vaccination against S. pneumoniae, H. influenzae type b, and influenza is recommended as
early as possible before the season of respiratory infections starts. Combined vaccination
against respiratory infections has more significant effects on clinical characteristics and
functional status of COPD patients and promotes production of specific antibodies not only
against vaccine strains of influenza virus but also against S. pneumoniae and H. influenzae
antigens contained in the corresponding vaccines.
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